Literature DB >> 12216018

Charnley low-friction arthroplasty: a worldwide retrospective review at 15 to 20 years.

John Older1.   

Abstract

This is a retrospective survivorship analysis review of 5089 Charnley low-friction arthroplasties performed as a primary procedure at 8 hospitals around the world before December 31, 1980. Data collected were simple with a well-defined endpoint: death or revision. There was no clinical or radiographic evaluation. The mean age at operation was 63 years; 57% of hips were in women, and 43% were in men. The preoperative diagnosis was primary osteoarthrosis in 74% of hips. Kaplan-Meier survivorship analysis using failure as revision of any component for any cause showed probability of survival at 20 years of 83% (women, 86%, and men, 78%). In patients aged 70 to 80 at surgery, probability of survival was 92%; in patients aged < or =40, probability of survival was 67%. This study showed almost identical durability of the femoral versus acetabular component-87%. Copyright 2002, Elsevier Science (USA).

Entities:  

Mesh:

Year:  2002        PMID: 12216018     DOI: 10.1054/arth.2002.31973

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  18 in total

1.  Revision for taper corrosion at the neck-body junction following total hip arthroplasty: pearls and pitfalls.

Authors:  Mitchell C Weiser; Darwin D Chen
Journal:  Curr Rev Musculoskelet Med       Date:  2016-03

2.  Hip resurfacing arthroplasty: risk factors for failure over 25 years.

Authors:  Eric J Yue; Miguel E Cabanela; Gavan P Duffy; Michael G Heckman; Mary I O'Connor
Journal:  Clin Orthop Relat Res       Date:  2008-09-24       Impact factor: 4.176

Review 3.  Correlation between patient age at total hip replacement surgery and lifeexpectancy.

Authors:  Carlos Roberto Schwartsmann; Leandro de Freitas Spinelli; Leonardo Carbonera Boschin; Anthony Kerbes Yépez; Marcus Vinicius Crestani; Marcelo Faria Silva
Journal:  Acta Ortop Bras       Date:  2015 Nov-Dec       Impact factor: 0.513

4.  Bony anatomy of the third metacarpal and relationship with the capitate: a computed tomography study.

Authors:  Rudolph G Venter; Marilize C Burger; Ajmal Ikram; Robert P Lamberts
Journal:  Surg Radiol Anat       Date:  2019-06-27       Impact factor: 1.246

Review 5.  Macrophages-Key cells in the response to wear debris from joint replacements.

Authors:  Christophe Nich; Yuya Takakubo; Jukka Pajarinen; Mari Ainola; Abdelhakim Salem; Tarvo Sillat; Allison J Rao; Milan Raska; Yasunobu Tamaki; Michiaki Takagi; Yrjö T Konttinen; Stuart B Goodman; Jiri Gallo
Journal:  J Biomed Mater Res A       Date:  2013-04-09       Impact factor: 4.396

6.  Low friction arthroplasty and dual mobility cup: a new gold standard.

Authors:  Jean Louis Prudhon; Régis Verdier; Jacques H Caton
Journal:  Int Orthop       Date:  2016-12-20       Impact factor: 3.075

7.  The Exeter Universal hip in patients 50 years or younger at 10-17 years' followup.

Authors:  Simon C Lewthwaite; Ben Squires; Graham A Gie; Andrew J Timperley; Robin S M Ling
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

8.  Total hip arthroplasties: what are the reasons for revision?

Authors:  Slif D Ulrich; Thorsten M Seyler; Derek Bennett; Ronald E Delanois; Khaled J Saleh; Issada Thongtrangan; Michael Kuskowski; Edward Y Cheng; Peter F Sharkey; Javad Parvizi; James B Stiehl; Michael A Mont
Journal:  Int Orthop       Date:  2007-04-19       Impact factor: 3.075

9.  Quantifying wear depth in hip prostheses using a 3D optical scanner.

Authors:  Katherine A Hollar; Daniel S Ferguson; John B Everingham; Jillian L Helms; Kevin J Warburton; Trevor J Lujan
Journal:  Wear       Date:  2017-10-16       Impact factor: 3.892

Review 10.  Risk factors for revision of primary total hip arthroplasty: a systematic review.

Authors:  Julian Jz Prokopetz; Elena Losina; Robin L Bliss; John Wright; John A Baron; Jeffrey N Katz
Journal:  BMC Musculoskelet Disord       Date:  2012-12-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.